Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
U.S. Physical Therapy, Inc., together with its subsidiaries, operates and manages outpatient physical therapy clinics. It operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. U.S. Physical Therapy, Inc. was founded in 1990 and is based in Houston, Texas.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $781M | $110M | $15M | $61M | 3.2% | 16.3% | -43.1% |
| 2024 | $671M | $87M | $26M | $66M | 5.4% | 11.0% | 80.3% |
| 2023 | $605M | $74M | $15M | $73M | 3.1% | 9.3% | -48.1% |
| 2022 | $553M | $76M | $28M | $50M | 9.0% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 780.99 |
| Operating Revenue | 650.43 |
| Cost Of Revenue | 631.30 |
| Gross Profit | 149.69 |
| Operating Expense | 69.26 |
| Selling General And Administration | - |
| Total Expenses | 700.56 |
| Operating Income | 80.43 |
| Total Operating Income As Reported | 86.68 |
| EBITDA | 109.66 |
| Normalized EBITDA | 104.86 |
| EBIT | 87.27 |
| Interest Income | 0.10 |
| Interest Expense | 9.46 |
| Net Interest Income | -9.35 |
| Other Non Operating Income Expenses | 0.46 |
| Other Income Expense | 6.73 |
| Interest Income Non Operating | 0.10 |
| Interest Expense Non Operating | 9.46 |
| Net Non Operating Interest Income Expense | -9.35 |
| Pretax Income | 77.81 |
| Tax Provision | 19.81 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 1.22 |
| Net Income Continuous Operations | 58 |
| Net Income From Continuing And Discontinued Operation | 15.06 |
| Net Income From Continuing Operation Net Minority Interest | 15.06 |
| Net Income | 15.06 |
| Net Income Common Stockholders | 21.57 |
| Net Income Including Noncontrolling Interests | 58 |
| Normalized Income | 11.48 |
| Diluted NI Availto Com Stockholders | 21.57 |
| Basic Average Shares | 15.18 |
| Diluted Average Shares | 15.18 |
| Reconciled Depreciation | 22.39 |
| Reconciled Cost Of Revenue | 631.30 |
| Total Unusual Items | 4.80 |
| Total Unusual Items Excluding Goodwill | 4.80 |
| Minority Interests | -42.94 |
| Special Income Charges | 6.12 |
| Gain On Sale Of Business | -0.12 |
| Other Special Charges | - |
| Write Off | 0 |
| Impairment Of Capital Assets | 0 |
| Restructuring And Mergern Acquisition | -6.24 |
| Gain On Sale Of Security | -1.32 |
| General And Administrative Expense | - |
| Other Gand A | - |
| Rent Expense Supplemental | 140.43 |
| Other Operating Expenses | 69.26 |
| Otherunder Preferred Stock Dividend | -6.51 |
| Earnings From Equity Interest | 1.48 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| U.S. Physical Therapy, Inc.this co. | USPH | $940M | 62.41 | 1.97 | 3.2% | 11.12 |
| Corvus Pharmaceuticals, Inc. | CRVS | $986M | -64.49 | 16.10 | -25.0% | -22.91 |
| InnovAge Holding Corp. | INNV | $977M | -32.24 | 4.16 | -12.9% | -102.40 |
| Anteris Technologies Global Corp. | AVR | $939M | - | 48.67 | -238.4% | - |
| Olema Pharmaceuticals, Inc. | OLMA |
| - |
| - |
| - |
| - |
| - |
| - |
| $933M |
| -5.74 |
| 1.95 |
| -33.9% |
| -4.99 |
| Nutex Health Inc. | NUTX | $930M | 13.13 | 2.82 | 21.5% | 3.81 |
| ARS Pharmaceuticals, Inc. | SPRY | $901M | -5.26 | 7.88 | -149.9% | -5.66 |
| Annexon, Inc. | ANNX | $893M | -4.32 | 4.22 | -97.7% | -3.54 |
| Pacira BioSciences, Inc. | PCRX | $892M | 126.89 | 1.29 | 1.0% | 8.75 |
| Peer Median | - | -5.26 | 4.19 | -29.5% | -4.99 | |